5,844 Shares in Abbott Laboratories $ABT Purchased by Ransom Advisory Ltd

Key Points

• Ransom Advisory Ltd has acquired a new position in Abbott Laboratories, purchasing 5,844 shares valued at approximately $775,000 in the first quarter.
• Multiple institutional investors, including Nuveen LLC and Goldman Sachs Group Inc., have significantly increased their stakes in Abbott Laboratories, with 75.18% of the company's stock now held by institutional investors.
• Abbott Laboratories reported a net margin of 32.43% and set its FY 2025 guidance at 5.100-5.200 EPS, showing strong financial performance in the recent quarter.

Ransom Advisory Ltd acquired a new position in Abbott Laboratories (NYSE:ABT - Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 5,844 shares of the healthcare product maker's stock, valued at approximately $775,000.

A number of other large investors have also modified their holdings of ABT. Brighton Jones LLC raised its position in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock worth $5,850,000 after acquiring an additional 4,755 shares during the period. Bank Pictet & Cie Europe AG raised its position in shares of Abbott Laboratories by 1.9% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock worth $17,274,000 after purchasing an additional 2,774 shares during the last quarter. MJP Associates Inc. ADV raised its position in shares of Abbott Laboratories by 7.2% during the 4th quarter. MJP Associates Inc. ADV now owns 2,367 shares of the healthcare product maker's stock worth $268,000 after purchasing an additional 160 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Abbott Laboratories by 6.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 168,417 shares of the healthcare product maker's stock worth $19,050,000 after purchasing an additional 10,933 shares during the last quarter. Finally, Minot DeBlois Advisors LLC acquired a new position in shares of Abbott Laboratories during the 4th quarter worth about $1,445,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Morgan Stanley upped their price target on shares of Abbott Laboratories from $127.00 to $137.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. Leerink Partnrs raised shares of Abbott Laboratories to a "hold" rating in a research note on Monday, June 16th. Wells Fargo & Company dropped their price target on shares of Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating for the company in a research note on Friday, July 18th. Jefferies Financial Group raised shares of Abbott Laboratories from a "hold" rating to a "buy" rating and increased their price objective for the stock from $143.00 to $145.00 in a research report on Friday, July 18th. Finally, Raymond James Financial decreased their price target on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a research report on Friday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $144.47.

Insider Activity

In related news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Stock Performance

NYSE ABT traded down $1.62 during trading on Monday, reaching $132.11. The company's stock had a trading volume of 1,126,192 shares, compared to its average volume of 6,644,880. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The business's fifty day moving average price is $130.41 and its 200-day moving average price is $131.25. The firm has a market cap of $229.93 billion, a price-to-earnings ratio of 16.56, a P/E/G ratio of 2.54 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. During the same period in the previous year, the business posted $1.14 earnings per share. The business's revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.